Literature DB >> 29580859

Stage IV melanoma of unknown primary: A population-based study in the United States from 1973 to 2014.

Jeffrey F Scott1, Ruzica Z Conic2, Cheryl L Thompson3, Meg R Gerstenblith2, Jeremy S Bordeaux2.   

Abstract

BACKGROUND: Melanoma of unknown primary (MUP) is incompletely described on a population level.
OBJECTIVE: We sought to characterize stage IV MUP in a population-based cancer registry.
METHODS: We developed a novel search algorithm to identify cases of stage IV MUP in the Surveillance, Epidemiology, and End Results 18 registries from 1973 to 2014. Cases of stage IV melanoma of known primary (MKP) served as a comparison group. Age-standardized incidence rates, demographic characteristics, adjusted disease-specific survival, and Cox proportional hazard models were calculated for MUP and MKP.
RESULTS: A total of 322 stage IV MUP cases and 12,796 stage IV MKP cases were identified in Surveillance, Epidemiology, and End Results 18 registries from 1973 to 2014. The incidence of stage IV MUP is increasing, particularly for patients younger than 30 years of age. In multivariate analyses, age older than 50 and a lack of surgical treatment were negative prognostic factors for stage IV MUP. Relative survival, but not 5-year adjusted disease-specific survival, was higher for stage IV MUP than for MKP. LIMITATIONS: Limitations include the retrospective study design and possible misclassification of MUP.
CONCLUSIONS: The incidence of stage IV MUP is increasing, and stage IV MUP shares similar prognostic factors with stage IV MKP, including age and surgical treatment.
Copyright © 2018 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Surveillance, Epidemiology, and End Results 18; melanoma of unknown primary

Mesh:

Year:  2018        PMID: 29580859      PMCID: PMC6050094          DOI: 10.1016/j.jaad.2018.03.021

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  30 in total

1.  MALIGNANT MELANOMA OF UNKNOWN PRIMARY ORIGIN.

Authors:  T DASGUPTA; L BOWDEN; J W BERG
Journal:  Surg Gynecol Obstet       Date:  1963-09

2.  Distinct sets of genetic alterations in melanoma.

Authors:  John A Curtin; Jane Fridlyand; Toshiro Kageshita; Hetal N Patel; Klaus J Busam; Heinz Kutzner; Kwang-Hyun Cho; Setsuya Aiba; Eva-Bettina Bröcker; Philip E LeBoit; Dan Pinkel; Boris C Bastian
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

Review 3.  Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature.

Authors:  K Kamposioras; G Pentheroudakis; D Pectasides; N Pavlidis
Journal:  Crit Rev Oncol Hematol       Date:  2010-05-31       Impact factor: 6.312

4.  Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma: recommendations for initial staging examinations.

Authors:  B Schlagenhauff; W Stroebel; U Ellwanger; F Meier; C Zimmermann; H Breuninger; G Rassner; C Garbe
Journal:  Cancer       Date:  1997-07-01       Impact factor: 6.860

5.  Genomic Classification of Cutaneous Melanoma.

Authors: 
Journal:  Cell       Date:  2015-06-18       Impact factor: 41.582

6.  Melanoma of unknown primary is correctly classified by the AJCC melanoma classification from 2009.

Authors:  Anne F Pfeil; Ulrike Leiter; Petra G Buettner; Thomas K Eigentler; Benjamin Weide; Friedegund Meier; Claus Garbe
Journal:  Melanoma Res       Date:  2011-06       Impact factor: 3.599

7.  On crude and age-adjusted relative survival rates.

Authors:  Hermann Brenner; Timo Hakulinen
Journal:  J Clin Epidemiol       Date:  2003-12       Impact factor: 6.437

8.  Melanomas of unknown primary frequently harbor TERT-promoter mutations.

Authors:  Friederike Egberts; Sandra Krüger; Hans M Behrens; Inka Bergner; Giorgios Papaspyrou; Jochen A Werner; Ibrahim Alkatout; Jochen Haag; Axel Hauschild; Christoph Röcken
Journal:  Melanoma Res       Date:  2014-04       Impact factor: 3.599

9.  Malignant melanoma primary in lymph node. The case of the missing link.

Authors:  B V Shenoy; L Fort; S P Benjamin
Journal:  Am J Surg Pathol       Date:  1987-02       Impact factor: 6.394

10.  Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts.

Authors:  Sarah A Weiss; Joseph Han; Farbod Darvishian; Jeremy Tchack; Sung Won Han; Karolina Malecek; Michelle Krogsgaard; Iman Osman; Judy Zhong
Journal:  J Transl Med       Date:  2016-10-19       Impact factor: 5.531

View more
  5 in total

1.  Metastatic Melanoma of Uncertain Primary with 5-Year Durable Response after Conventional Therapy: A Case Report with Literature Review.

Authors:  Jomjit Chantharasamee; Jitsupa Treetipsatit
Journal:  Case Rep Oncol Med       Date:  2018-05-31

2.  Patients with melanoma of unknown primary show better outcome under immune checkpoint inhibitor therapy than patients with known primary: preliminary results.

Authors:  Thilo Gambichler; Maria Chatzipantazi; Ulrike Schröter; E Stockfleth; Cansu Gedik
Journal:  Oncoimmunology       Date:  2019-10-21       Impact factor: 8.110

3.  Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: A Dutch population-based study.

Authors:  D Verver; Aam van der Veldt; Acj van Akkooi; C Verhoef; D J Grünhagen; W J Louwman
Journal:  Int J Cancer       Date:  2019-03-20       Impact factor: 7.396

4.  Metastatic melanoma of unknown origin mimicking neurofibromatosis.

Authors:  Lauren Chen; Celeste Newby; Nibras Fakhri; Markus Lammle
Journal:  Radiol Case Rep       Date:  2020-11-10

5.  Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy.

Authors:  Danielle Verver; Dirk J Grünhagen; Alexander C J van Akkooi; Maureen J B Aarts; Franchette W P J van den Berkmortel; Alfonsus J M van den Eertwegh; Jan Willem B de Groot; Marye J Boers-Sonderen; John B A G Haanen; Geke A P Hospers; Ellen Kapiteijn; Djura Piersma; Rozemarijn S van Rijn; Karijn P M Suijkerbuijk; Albert J Ten Tije; Gerard Vreugdenhil; Cornelis Verhoef; Astrid A M van der Veldt
Journal:  Cancer Immunol Immunother       Date:  2021-03-27       Impact factor: 6.968

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.